Imaging-guided Curative Surgical Resection of Pancreatic Cancer in a Xenograft Mouse Model

Overview

Journal Cancer Lett

Specialty Oncology

Date 2012 May 24

PMID 22617626

Citations 19

Authors

Xiaoling Ni

Jingxuan Yang

Min Li

Affiliations

Soon will be listed here.

Abstract

Pancreatic cancer is the fourth leading cause of cancer related deaths in North America. The poor survival statistics are due to the fact that there are no reliable tests for early diagnosis and no effective therapies once metastasis has occurred. Surgical resection is the only curative treatment for pancreatic cancer; however, only less than 15% of the patients are eligible for surgery at diagnosis. New therapies are urgently needed for this malignant disease. And combinational therapy including surgery, chemotherapy and molecular targeted therapy may further improve the efficacy of individual therapies. However, a reliable mouse model which mimics the human disease and can be used for testing the surgical treatment and surgery-based combinational therapy is not available. In this study, we have established a mouse model for curative surgical resection of pancreatic cancer. Human pancreatic cancer cells were used to create orthotopic xenografts in nude mice, distal pancreatectomy was performed using imaging-guided technology to remove the pancreatic tumors, and sham surgery was performed in the control group. All mice survived the operation and no complication was observed. Surgical resection at early stage improved the survival rate and quality of life of the mice compared with the sham surgery and surgical resection at the late stage. If combined with other therapies such as chemotherapy and molecular targeted therapy, it could further improve the outcome of pancreatic cancer. This mouse model is a useful tool to study the surgical therapy and the tumor recurrence of pancreatic cancer, and could potentially impact the therapeutic choices for this deadly disease.

Citing Articles

Convergent insulin and TGF-β signalling drives cancer cachexia by promoting aberrant fat body ECM accumulation in a Drosophila tumour model.

Bakopoulos D, Golenkina S, Dark C, Christie E, Sanchez-Sanchez B, Stramer B EMBO Rep. 2023; 24(12):e57695.

PMID: 38014610 PMC: 10702797. DOI: 10.15252/embr.202357695.

A prognostic model based on tumor microenvironment-related lncRNAs predicts therapy response in pancreatic cancer.

Lu J, Tan J, Yu X Funct Integr Genomics. 2023; 23(1):32.

PMID: 36625842 DOI: 10.1007/s10142-023-00964-x.

Three categories of similarities between the placenta and cancer that can aid cancer treatment: Cells, the microenvironment, and metabolites.

Pang H, Lei D, Guo Y, Yu Y, Liu T, Liu Y Front Oncol. 2022; 12:977618.

PMID: 36059660 PMC: 9434275. DOI: 10.3389/fonc.2022.977618.

Tumor cell anabolism and host tissue catabolism-energetic inefficiency during cancer cachexia.

Hegde M, Daimary U, Girisa S, Kumar A, Kunnumakkara A Exp Biol Med (Maywood). 2022; 247(9):713-733.

PMID: 35521962 PMC: 9134760. DOI: 10.1177/15353702221087962.

Understanding cachexia in the context of metastatic progression.

Biswas A, Acharyya S Nat Rev Cancer. 2020; 20(5):274-284.

PMID: 32235902 DOI: 10.1038/s41568-020-0251-4.

References

Kim J, Hur H, Kim N, Kim Y, Cho S, Kim J . Oncologic outcomes after radical surgery following preoperative chemoradiotherapy for locally advanced lower rectal cancer: abdominoperineal resection versus sphincter-preserving procedure. Ann Surg Oncol. 2009; 16(5):1266-73. DOI: 10.1245/s10434-009-0338-3. View

Ni X, Long J, Cen P, Chen L, Yang J, Li M . Pancreatic cancer tumour initiating cells: the molecular regulation and therapeutic values. J Cell Mol Med. 2011; 16(5):988-94. PMC: 3298733. DOI: 10.1111/j.1582-4934.2011.01478.x. View

Torgenson M, Shea J, Firpo M, Dai Q, Mulvihill S, Scaife C . Natural history of pancreatic cancer recurrence following "curative" resection in athymic mice. J Surg Res. 2008; 149(1):57-61. DOI: 10.1016/j.jss.2007.08.024. View

Liu S, Patel S, Gingras M, Nemunaitis J, Zhou G, Chen C . PDX-1: demonstration of oncogenic properties in pancreatic cancer. Cancer. 2010; 117(4):723-33. PMC: 3017729. DOI: 10.1002/cncr.25629. View

Hingorani S, Wang L, Multani A, Combs C, Deramaudt T, Hruban R . Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell. 2005; 7(5):469-83. DOI: 10.1016/j.ccr.2005.04.023. View

Siegel R, Naishadham D, Jemal A . Cancer statistics, 2012. CA Cancer J Clin. 2012; 62(1):10-29. DOI: 10.3322/caac.20138. View

Sebag-Montefiore D, Stephens R, Steele R, Monson J, Grieve R, Khanna S . Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet. 2009; 373(9666):811-20. PMC: 2668947. DOI: 10.1016/S0140-6736(09)60484-0. View

Bujko K, Nowacki M, Nasierowska-Guttmejer A, Michalski W, Bebenek M, Kryj M . Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg. 2006; 93(10):1215-23. DOI: 10.1002/bjs.5506. View

Izeradjene K, Combs C, Best M, Gopinathan A, Wagner A, Grady W . Kras(G12D) and Smad4/Dpc4 haploinsufficiency cooperate to induce mucinous cystic neoplasms and invasive adenocarcinoma of the pancreas. Cancer Cell. 2007; 11(3):229-43. DOI: 10.1016/j.ccr.2007.01.017. View

10.

Li M, Zhang Y, Bharadwaj U, Zhai Q, Ahern C, Fisher W . Down-regulation of ZIP4 by RNA interference inhibits pancreatic cancer growth and increases the survival of nude mice with pancreatic cancer xenografts. Clin Cancer Res. 2009; 15(19):5993-6001. PMC: 2756333. DOI: 10.1158/1078-0432.CCR-09-0557. View

11.

Chen W, Horoszewicz J, Leong S, Shimano T, Penetrante R, Sanders W . Human pancreatic adenocarcinoma: in vitro and in vivo morphology of a new tumor line established from ascites. In Vitro. 1982; 18(1):24-34. DOI: 10.1007/BF02796382. View

12.

Shi S, Yao W, Xu J, Long J, Liu C, Yu X . Combinational therapy: new hope for pancreatic cancer?. Cancer Lett. 2011; 317(2):127-35. DOI: 10.1016/j.canlet.2011.11.029. View

13.

Long J, Zhang Y, Yu X, Yang J, LeBrun D, Chen C . Overcoming drug resistance in pancreatic cancer. Expert Opin Ther Targets. 2011; 15(7):817-28. PMC: 3111812. DOI: 10.1517/14728222.2011.566216. View

14.

Eibl G, Reber H . A xenograft nude mouse model for perineural invasion and recurrence in pancreatic cancer. Pancreas. 2005; 31(3):258-62. DOI: 10.1097/01.mpa.0000175176.40045.0f. View

15.

Wong R, Tandan V, De Silva S, Figueredo A . Pre-operative radiotherapy and curative surgery for the management of localized rectal carcinoma. Cochrane Database Syst Rev. 2007; (2):CD002102. DOI: 10.1002/14651858.CD002102.pub2. View

16.

Zhang Y, Bharadwaj U, Logsdon C, Chen C, Yao Q, Li M . ZIP4 regulates pancreatic cancer cell growth by activating IL-6/STAT3 pathway through zinc finger transcription factor CREB. Clin Cancer Res. 2010; 16(5):1423-30. PMC: 2841320. DOI: 10.1158/1078-0432.CCR-09-2405. View

17.

Ji Q, Hao X, Zhang M, Tang W, Yang M, Li L . MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. PLoS One. 2009; 4(8):e6816. PMC: 2729376. DOI: 10.1371/journal.pone.0006816. View

18.

Yu X, Zhang Y, Chen C, Yao Q, Li M . Targeted drug delivery in pancreatic cancer. Biochim Biophys Acta. 2009; 1805(1):97-104. PMC: 2815202. DOI: 10.1016/j.bbcan.2009.10.001. View

19.

Liu S, Ballian N, Belaguli N, Patel S, Li M, Templeton N . PDX-1 acts as a potential molecular target for treatment of human pancreatic cancer. Pancreas. 2008; 37(2):210-20. DOI: 10.1097/MPA.0b013e31816a4a33. View

20.

Li M, Zhang Y, Liu Z, Bharadwaj U, Wang H, Wang X . Aberrant expression of zinc transporter ZIP4 (SLC39A4) significantly contributes to human pancreatic cancer pathogenesis and progression. Proc Natl Acad Sci U S A. 2007; 104(47):18636-41. PMC: 2141829. DOI: 10.1073/pnas.0709307104. View